University Hospital Leipzig
Leipzig, Germany 
Head of the Department
Prof. Dr. Uwe Platzbecker
Department of Hematology and Cell Therapy, Medical Oncology and Hemostaseology
Department of Hematology and Cell Therapy, Medical Oncology and Hemostaseology at University Hospital Leipzig provides care for patients with blood clotting disorders, blood malignancies and tumors of solid tumors. The department is certified by the German Cancer Center and is composed of one station for hematology and oncology, another for hematology and cell therapy, two stations for stem cell transplantation and one intensive care unit where critical conditions are handled and cared for. The department is also recognized by the DGHO German Society for Hematology and Medical Oncology eV as it has specialized teams and equipment for the treatment of leukemia, clotting disorders, lymphoid neoplasia, stem cell transplantations, and organ cancer.
Under the guidance of Prof. Dr. Med. Uwe Platzbecker, the department treated over 1,250 inpatients every year. The department is also a part of the University Cancer Center Leipzig where patients have a specialized team of doctors working together to reach a rapid, accurate diagnosis as well as formulate a treatment plan that’s specialized for each patient's condition.
The Hematology and Cell Therapy, Medical Oncology and Hemostaseology at University Hospital Leipzig is specialized in the diagnosis and treatment of:
• Acute and chronic leukemia
• Myelodysplastic syndrome
• Lymphoma
• Myeloproliferative disease
• Polycythemia
• Multiple myeloma
• Osteosarcoma
• Solid-organ tumors
• Soft tissue tumors
• Myeloma
• Clotting disorders
• Idiopathic thrombocytopenia
• Thalassemia
• Anemia
Education and training
- 1996 Final degree in Medicine from University Hospital “Carl Gustav Carus” at the TU Dresden
- 1997 MD degree from Medicine University Hospital “Carl Gustav Carus” at the TU Dresden
- 2002 Postdoctoral degree from Medicine Fred Hutchinson Cancer Research Center, Seattle
- 2005 Board certification in Internal Medicine from University Hospital “Carl Gustav Carus” at the TU Dresden
- 2007 Board certification in Hematology / Oncology from University Hospital “Carl Gustav Carus” at the TU Dresden
- 2008 Board certification in Palliative Medicine from University Hospital “Carl Gustav Carus” at the TU Dresden
- 2008 Board certification in Hemostaseology from University Hospital “Carl Gustav Carus” at the TU Dresden
Positions and honors
- Since Oct 2018 Director of the Medical Clinic I, Hematology and Cell Therapy at the University Hospital in Leipzig
- 2015-Sept 2018 Transcampus Professor of Hematology at the Faculty of Life Science and Medicine at King’s College London (UK)
- 2014-2018 Head of the section of hematology, Dept. of Internal Medicine I, University Hospital “Carl Gustav Carus” at the TU Dresden
- 2012-2018 Appointment as Professor of Translational Hematology (W2), TU Dresden
- 2006 Habilitation (Privatdozent)
- 2005-2012 Senior physician and Head of Hematology out-patient department, Dept. of Internal Medicine I, University Hospital “Carl Gustav Carus” at the TU Dresden
- 2002-2005 Dept. of Internal Medicine I, University Hospital “Carl Gustav Carus”, at the TU Dresden
- 2001-2002 Postdoc supported by the Humboldt-Foundation (Feodor Lynen Project) at the Fred Hutchinson Cancer Research Center, Prof. Dr. Deeg, Seattle, USA
- 1998-2001 Dept. of Internal Medicine I, University Hospital “Carl Gustav Carus” at the TU Dresden
- 1998 Medical practice for Radiology, Grosche/Hupke/Lautenbach, Dresden
- 1996-1998 Heart Center Dresden, Clinic for Cardio-and Thoracic Vascular Surgery, TU Dresden
Professional appointments:
- Since 2016 Member of the MDS Foundation’s Medical & Scientific Advisory Board
- 2014-2018 Chair medical ethics committee of the TU Dresden
- Since 2013 Chairman of the European Myelodysplastic Syndromes Cooperative Group (EMSCO) by the ELN
- Since 2012 Co-Chairman MDS EHA SWG (Chair: P. Fenaux)
Memberships:
- Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)
- American Society of Hematology (ASH)
- European Haematology Association (EHA)
- Study Alliance Leukemia (SAL)
- Deutsch-Österreichisch-Schweizerische MDS Studiengruppe (DACH)
- European Leukemia Net (ELN)
- Gesellschaft für Thrombose und Hämostaseologie (GTH)
Honors
- 2014 EHA educational presentation
- 2013 ASH educational presentation
- 2012 Poster award, DGHO
- 2010 Best Abstract, European Leukemia Net meeting
- 2009 Poster award, 10th International Symposium on MDS
- 2006 Travel award, American Society of Hematology (ASH)
- 2006 Chugai Science Award
Selected publications
- Platzbecker U et al. Measurable-residual disease guided treatment with azacitidine to prevent hematological relapse in patients with MDS and AML – results from the multicenter phase 2 RELAZA2 trial. Lancet Oncol. 2018, in press.
- Platzbecker U et al. Luspatercept for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017 Oct;18(10):1338-1347.
- Platzbecker U et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukemia: a multicentre, randomized, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol. 2015 Oct;2(10):e417-26
- Lo-Coco F, et al…, Platzbecker U. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21.
- Platzbecker U et al. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol. 2017 Feb 20;35(6):605- 612.
- Platzbecker U et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012 Mar;26(3):381-9
Department of Hematology and Cell Therapy, Medical Oncology and Hemostaseology
Receive an offer for Treatments
